INS and type 1 diabetes mellitus: It has been reported that a single course of treatment with anti-CD3 mAb, hOKT3gamma1(Ala-Ala), can help preserve insulin production in new-onset type 1 diabetes patients for longer than 1 year after administration [249, 250].